Kennedy Capital Management Inc Trimmed Position in Cambrex Corporation (NYSE:CBM) by $10.05 Million as Price Rose

May 16, 2018 - By Benjamin Allen

During 2017 Q4 the big money sentiment decreased to 1.15. That’s change of 0.43, from 2017Q3’s 1.58. 33 investors sold all, 71 reduced holdings as CBM ratio fall. 82 grew positions while 38 funds acquired positions. Funds hold 32.02 million shares thus 1.25% more from 2017Q3’s 31.63 million shares. Cubist Systematic Strategies invested in 0.02% or 8,362 shs. Zebra Cap Management Limited Liability has invested 0.16% in Cambrex Corporation (NYSE:CBM). Pillar Pacific Capital Ltd Liability Corp reported 7,350 shs stake. Ontario – Canada-based Bankshares Of Montreal Can has invested 0% in Cambrex Corporation (NYSE:CBM). Two Sigma Secs Lc, New York-based fund reported 4,309 shs. 153,135 are owned by Jpmorgan Chase And. Bb&T Secs has 5,660 shs. Cornerstone accumulated 290 shs. Legal And General Gru Pcl stated it has 67,389 shs. Point72 Asia (Hong Kong) stated it has 0.01% of its capital in Cambrex Corporation (NYSE:CBM). 20,382 were reported by Thrivent Finance For Lutherans. Rmb Cap Management Ltd Co accumulated 113,015 shs. Piedmont Invest Ltd Liability Corporation has invested 0.01% of its capital in Cambrex Corporation (NYSE:CBM). Fdx stated it has 0.01% of its capital in Cambrex Corporation (NYSE:CBM). Mai Capital holds 15,895 shs or 0.04% of its capital.

CBM registered $5.33 million net activity with 0 buys and 2 selling transactions since May 7, 2018. SARGEN GREGORY sold 67,500 shs worth $3.34M.

Based on the latest 2018Q1 regulatory filing with the SEC, Kennedy Capital Management Inc reduced its stake in Cambrex Corporation (NYSE:CBM) by 44.09%. 193,214 shares were sold by Kennedy Capital Management Inc as the company’s stock rose 5.58% while stock markets declined. At the end of 2018Q1, the 244,994 shares of the major pharmaceuticals company held by the institutional investor were valued at $12.81 million, down from 438,208 at the end of the previous reported quarter. Cambrex Corporation has $1.58 billion market cap. Ticker’s shares touched $47.95 during the last trading session after 0.62% change.Cambrex Corporation has volume of 228,337 shares. Since May 17, 2017 CBM has risen 2.87% and is uptrending. CBM underperformed by 8.68% the S&P 500.

For a total of 600,021 shares it increased its holding in Biotelemetry Inc (NASDAQ:BEAT) by 458,774 shares in the quarter, and has risen its stake in Simmons First National Corporation Cl A (NASDAQ:SFNC).

Kennedy Capital Management Inc is a Missouri-based institutional investor with more than $5.67 billion AUM in March, 2014. Taken from Kennedy Capital Management latest Adv, the fund reported to have 50 full and part-time employees. Among which 31 performing investment advisory and research functions. The institutional investor had more than 500 clients.

Cambrex Corporation (NYSE:CBM) Ratings Coverage

In total 2 analysts cover Cambrex Corp (NYSE:CBM). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. (NYSE:CBM) has 50% bullish analysts. 2 are the (NYSE:CBM)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Tuesday, January 16 the firm has “Buy” rating given by William Blair. On Wednesday, February 14 the stock has “Neutral” rating by Longbow.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide.The firm is worth $1.58 billion. The Company’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.The P/E ratio is 15.66. The firm serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Cambrex Corporation (NYSE:CBM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.